BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Shenzhen Salubris Pharmaceuticals readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Shenzhen Salubris Pharmaceuticals
 's drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07729475-1077@assetmemo.bio
DTSTAMP:20261121T010121Z
DTSTART;VALUE=DATE:20261212
DTEND;VALUE=DATE:20261213
SUMMARY:SAL0137: Phase 2 readout est. (NCT07729475)
DESCRIPTION:SAL0137\, phase 2\, Atherosclerotic Cardiovascular Disease.\nSt
 udy: A Phase II\, Randomized\, Double-Blind\, Placebo-Controlled Study of 
 Oral SAL0137 in Adults With Elevated Lp(a) and Increased Risk of Cardiovas
 cular Events\nEstimated primary completion: 12 December 2026. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/sal0137#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07729475
URL:https://assetmemo.bio/drug/sal0137#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07654140-944@assetmemo.bio
DTSTAMP:20261121T010121Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:SAL0140: Phase 2 readout est. (NCT07654140)
DESCRIPTION:SAL0140\, phase 2\, Hypertension.\nStudy: A Phase II Clinical T
 rial of Efficacy and Safety of SAL0140 at Different Doses in Patients With
  Uncontrolled Hypertension\nEstimated primary completion: 1 March 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/sal0140#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07654140
URL:https://assetmemo.bio/drug/sal0140#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07646535-944@assetmemo.bio
DTSTAMP:20261121T010121Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:SAL0140: Phase 2 readout est. (NCT07646535)
DESCRIPTION:SAL0140\, phase 2.\nStudy: A Phase II Clinical Trial of Efficac
 y and Safety of SAL0140 at Different Doses in Patients With Primary Aldost
 eronism\nEstimated primary completion: 1 April 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/sal0140#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07646535
URL:https://assetmemo.bio/drug/sal0140#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07647133-944@assetmemo.bio
DTSTAMP:20261121T010121Z
DTSTART;VALUE=DATE:20271008
DTEND;VALUE=DATE:20271009
SUMMARY:SAL0140: Phase 2 readout est. (NCT07647133)
DESCRIPTION:SAL0140\, phase 2\, Chronic Kidney Disease.\nStudy: A Phase II 
 Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Pat
 ients With Chronic Kidney Disease\nEstimated primary completion: 8 October
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/sal0140#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07647133
URL:https://assetmemo.bio/drug/sal0140#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07923357-487@assetmemo.bio
DTSTAMP:20261121T010121Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:SAL0150: Phase 2 readout est. (NCT07923357)
DESCRIPTION:SAL0150\, phase 2\, Type 2 Diabetes.\nStudy: A Phase 2 Study to
  Evaluate the Efficacy\, Safety\, and Pharmacokinetics of SAL0150 Tablets 
 in Subjects With Type 2 Diabetes Mellitus\nEstimated primary completion: 3
 0 November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sal0
 150#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07923357
URL:https://assetmemo.bio/drug/sal0150#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
